ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGEN Agenus Inc

12.95
0.00 (0.00%)
07 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agenus Inc NASDAQ:AGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 12.95 13.32 13.35 0 01:00:00

Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast

31/10/2019 4:04pm

PR Newswire (US)


Agenus (NASDAQ:AGEN)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agenus Charts.

LEXINGTON, Mass., Oct. 31, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and provide a business update.

To access the live call, dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International) and ask to be joined into the Agenus call. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/31794. A replay will be available on the Company's website approximately two hours after the call.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA.  For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Contact

Agenus Inc. 
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

Cision View original content:http://www.prnewswire.com/news-releases/agenus-to-report-third-quarter-2019-financial-results-on-november-4-2019-and-host-conference-call-and-webcast-300949271.html

SOURCE Agenus Inc.

Copyright 2019 PR Newswire

1 Year Agenus Chart

1 Year Agenus Chart

1 Month Agenus Chart

1 Month Agenus Chart

Your Recent History

Delayed Upgrade Clock